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The inhibition of some glutamate metabolic pathways could lead to diminished parasite survival. In this study, the eﬀects of L-
methionine sulfoximine (MS), DL-methionine sulfone (MSO),and DL-methionine sulfoxide (MSE), three glutamate analogs, on
several biological processes were evaluated. We found that these analogs inhibited the growth of epimastigotes cells and showed a
synergisticeﬀect withstressconditionssuchastemperature, nutritionalstarvation,andoxidativestress.Thespeciﬁc activityforthe
reductive amination of α-ketoglutaric acid, catalyzed by the NADP+-linked glutamate dehydrogenase, showed an increase in the
NADP+ levels, when MS, MSE, and MSO were added. It suggests an eventual conversion of the compounds tested by the T. cruzi
cells. The fact that trypomastigote bursting was not signiﬁcantlyinhibited when infected cells were treated with these compounds,
remarks the existence ofrelevant metabolic diﬀerences amongthe diﬀerent life-cycle stages. It must be considered when proposing
a new therapeutic drug.
1.Introduction
Chagas’ disease, also known as American trypanosomiasis, is
a parasitic illness caused by the hemoﬂagellate Trypanosoma
cruzi, which is transmitted to humans by blood-sucking
triatomine vectors. The parasite is prevalent in South and
Central America and infects 12–15 million people in the
region, with approximately 40,000 new cases per year, and
approximately 12,500 deaths per year due to cardiac disease
(WHO, http://www.who.int/tdr/). In addition, more than
100,000 chronically infected individuals currently reside in
theUnitedStates,Canada,andEuropeduetomigrationfrom
endemic countries [1]. At present, no clinically approved
drug exists for the satisfactory treatment of chronic stage
of the infection. Benznidazole and nifurtimox are the only
available drugs prescribed for T. cruzi and are 60–80% eﬀec-
tive in the treatment of acute infection, but the use of these
drugs to treat the chronic phase remains controversial due
to their low eﬀectiveness and high toxicity. As a consequence
of the adverse reactions, oral treatments frequently have to
be discontinued [2]. The limitations of existing therapies
encourage the search for alternative new drugs for both the
acute and chronic treatment of Chagas’ disease.
T. cruzi has a complex life cycle, alternating between the
insect vectorand themammalian vertebrate host, which may
includehumans.Theparasitepresentsdiﬀerentstagesduring
the cycle: epimastigotes (replicative and noninfective forms
in the insect vector), bloodstream and metacyclic trypo-
mastigotes (nonreplicative and infective forms to vertebrate
host cells), and amastigotes (intracellular and replicative
forms of the vertebrate host) [3–5]. These diﬀerent forms
of the parasite must adapt to the changes of the particular
environment inside the insect vector and vertebrate host
cells, such as temperature, pH, and nutrient availability.
Amino acids are crucial nutrients during the T. cruzi
life cycle, because they can be used as carbon and energy
sources [6] and can participate in severalbiologicalprocesses
that help the parasite adjust to these environmental changes.2 Enzyme Research
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Figure 1: Chemical structures of the compounds used in this study.
For example, arginine metabolism is coupled to T. cruzi
growth [7] and is involved in the management of cell energy
under conditions of pH and nutritional stress [8]. Proline,
glutamate, and aspartate are essentials in the diﬀerentiation
process from epimastigote to metacyclic trypomastigote
(metacyclogenesis) [9, 10]. More speciﬁcally, proline, an
amino acid metabolically related to glutamate, seems to
have a broad variety of functions: it fulﬁlls the energy
requirements for host cell invasion [11]a n dg r o w t hi nl o w -
glucose environments such as the host-cell cytoplasm [12],
it is involved in the diﬀerentiation from the intracellular
transient epimastigote-like stage to trypomastigote forms
[13], and recently, it has been shown to be involved in
mechanisms of resistance to oxidative stress [14]. The amino
acidglutamateisdirectlyinvolvedin osmoregulationandcell
volume control [15, 16]. Taking into account the important
biological functions of amino acids in T. cruzi, it has been
hypothesized that some components of their metabolic
pathways could serve as possible therapeutic targets against
Chagas’ disease [6].
The uptakeofglutamate occursin epimastigotes and try-
pomastigotes cells through a single kinetic transport system,
which is driven by the cytoplasmic membrane H+ concen-
tration gradient [17]. Inside the cell, it could be converted
into α-ketoglutarate by the glutamate dehydrogenase and
processed via the Krebs cycle to obtain energy [18–20]. Both
isoforms of this enzyme also participate in the biosynthesis
of glutamate by their ability to incorporate NH3 into α-
ketoglutarate [21]. According to nutritional requirements, T.
cruzi can incorporate L-glutamate into proteins, or transfer
thecarbon chain tothe metabolism ofarginine orproline via
Δ1-pyrroline-5-carboxylate dehydrogenase [6]. Interestingly,
L-glutamate can also serve as a substrate for glutathione
synthesis via γ-glutamylcysteine synthetase and glutathione
synthetase [22]. Glutathione can, in turn, act as a substrate
for the synthesis of trypanothione, a milestone metabolite
in the regulation of the redox state of the intracellular
medium in trypanosomas [23]. Furthermore, glutamine can
be synthesized from glutamate and ammonia in the presence
of glutamine synthetase [21]. As this reaction is reversible,
it is possible for glutamine to be oxidized through the
glutamate pathway. All these glutamate pathways could be
targets of inhibition by structural or functional analogs of
this amino acid, the common substrate of most of the key
enzymes related to glutamate metabolism.
The eﬀects of several glutamate analogs have been
analyzed in prokaryotic and eukaryotic organisms, showing
inhibitory eﬀects on some enzymatic functions. L-methio-
nine sulfoximine (MS), L-methionine sulfone (MSO), and
DL-methionine sulfoxide (MSE) (Figure 1)w e r ef o u n dt ob e
potentinhibitors of both enzymes, glutamatesynthetase [24]
and glutamine synthetase [25–27] in bacteria. In the present
w o r k ,w ea n a l y z et h ee ﬀects of three glutamate analogs MS,
MSE, and MSO on the growth and survival of T. cruzi
epimastigotes and on trypomastigote bursting from infected
host cells. We also investigated the synergism or antagonism
of these analogs with the thermal, oxidative, and nutritional
stress, conditions thatT. cruzi issubjectedto alongitsnatural
life cycle. The eﬀect of these compounds on the speciﬁc
activity for three glutamate-related enzymatic reactions was
also evaluated.
2.Resultsand Discussion
Thepossibletrypanocidalortrypanostaticeﬀectsofthethree
glutamate analogs, MS, MSE, and MSO, were investigated
in T. cruzi epimastigotes. The growth of epimastigotes on
LIT medium with or without 200μM rotenone and 0.5μM
antymicin [28] was used as a control. The epimastigotesEnzyme Research 3
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Figure 2: Growth curve of epimastigotes of Trypanosoma cruzi treated with MS (a), MSE (b) or MSO (c) at 28◦C and pH 7.5:
￿
0mM,
￿ MS=10mM, MSE=20mM, MSO=15 mM;   MS=20mM, MSE=40mM, MSO=30mM;
￿ MS=30mM, MSE=60mM,
MSO=45mM;
￿ MS=40mM, MSE=80mM, MSO=60mM;   MS=50mM, MSE=100mM, MSO=75mM. Positive control (•)w a s
used with 0.5μM antimycin and 200μM rotenone.
reached the maximum cell density, at values between 71 ±
4 ×106 cellsmL−1 and 108 ±2 × 106 cells mL−1, at the ninth
or tenth day of growth in LIT (Figure 2). All three glutamate
analogsshowedadose-dependentinhibitiononepimastigote
growth with signiﬁcant diﬀerences between the cells treated
with drugs and controls (P<. 01). The IC50 values estimated
at the ﬁfth day of growth were higher for MSO and MSE
(52.6±4.3mMand58.8±3.3mM,resp.)thanforMS(17.0±
0.3mM).MS and MSOarewell characterized as inhibitors of
prokaryotic and eukaryotic glutamine synthetase [25, 26, 29,
30], whereas MSE inhibits the enzyme glutamate synthetase
[24]. Since the IC50 values are high (more than 50-times)
when compared with the Km reported for the glutamate
transporter (0.3mM) [17], it seems that these compounds
are not acting as eﬃcient glutamate uptake inhibitors. On
the other hand, since measured enzyme activities are not
abolished, the fact that these compounds could be acting
with low eﬃciency on several targets cannot be ruled out.
Further experiments of glutamate and glutamine-uptake, in
the presence of MS, MSE and MSO as competitors, will be
done in order to determine if these transport systems are
inhibited.
Until now, no glutamate synthetase activity or putative
genes coding for this enzyme had been identiﬁed in
T. cruzi.H o w e v e r ,t h eT.cruzi NADP+-linked glutamate
dehydrogenase is a very well characterized enzyme, both at
molecular and biochemical level [18, 20, 31]. Previous
data have demonstrated the presence of the genes
coding (accession numbers: Tc00.1047053505843.10 and
Tc00.1047053508111.30 http://www.tritrypdb.org/)f o rt h e
NADP+-linked glutamate dehydrogenase on T. cruzi [32].
The ﬁrst of these alleles is the only one with published
data on the expression level along the T. cruzi life cy-
cle. It was found that the corresponding mRNA are4 Enzyme Research
downregulated in the trypomastigote stage and upregulated
in the epimastigote stage. No signiﬁcant variations were
reported for amastigotes or metacyclic trypomastigote
stages [33]. This enzyme catalyses reversibly the for-
mation of glutamate on T. cruzi. Adittionally, we have
identiﬁed two putative sequences for glutamine synthe-
tase (accession numbers: Tc00.1047053508175.370 and
Tc00.1047053503405.10, http://www.tritrypdb.org/). The
transcriptome analysis shows that the glutamine synthase
mRNA is down-regulated in the amastigote stage and
upregulated in the metacyclic trypomastigote stage with
respect to the epimastigote or trypomastigotes stages
[33]. Both essentiability and druggability parameters were
investigated in The TDR Targets Database v4 (http://www
.tdrtargets.org/) for both gene products: glutamate de-
hydrogenase and glutamine synthase. The only sequence for
which the data were available was that corresponding to the
glutamate dehydrogenase allele (Tc.00.1047053507875.20).
This sequence was deﬁned as a non-essential gene. In
a d d i t i o n ,n od r u g g a b i lity data were found.
The ﬁrst assumption of the functionality of a GS was
previously reported [21]. We conﬁrmed the functionality of
this biosynthetic step by measuring the GS speciﬁc activity
in crude extracts from epimastigotes forms (32 ± 3U/mg
protein, Figure 7(c)). The cloning of this genes and its
biochemical characterization are necessary to extrapolate
these data with the measurements in the parasite. However,
no signiﬁcant diﬀerences on the speciﬁc activity for GS were
observed in the presence of MS, MSE or MSO. The fact
that the IC50 values for both MSE and MSO are similar
gives support to the conversion of MSE into MSO [34], both
acting directly or indirectly on the same metabolic target. It
was also remarkable that the IC50 obtained for T. cruzi was
higher than that obtained for other organisms [24, 25, 30].
In view of this, it seems likely that these two compounds are
metabolized to molecules that are less toxic to the parasite,
or that are converted to methionine as described for some
bacteria, yeast, and mammalian organisms [35].
MS, which was proposed as a drug candidate against
tuberculosis [26, 27] and was successfully evaluated in
cancer therapy [36], showed the highest toxicity for T. cruzi
epimastigotes (17.0 ± 0.3mM). MS is a well-characterized
inhibitor of glutamine synthetase in mammalians [26, 27,
37, 38] that could cause an abnormal increase of glutamate
in astroglia, producing seizures and toxicity in animals [39].
However, no signiﬁcant inhibitory eﬀect was observed on
the GS activity, from T. cruzi,w h e nM So ro t h e ro n e
analog (MSE, MSO) were tested. In spite of requiring high
doses to inhibit T. cruzi growth, several factors aﬀecting MS
selectivity could be optimized based on several strategies. It
should be taken into account that the evaluated MS in this
study was the racemic form (S/R), which is the only one
commercially available. Usually, only one of the enantiomers
has biological activity. From previous studies, It is likely that
the S-enantiomer is active against glutamine synthetase [40].
A stereospeciﬁc preparation of this drug will probably result
in a 2- to 5-fold reduction of the IC50, as described for
Mycobacterium tuberculosis [26]. These data suggest that the
inhibitory eﬀect on T. cruzi demonstrated in this study could
Table 1: The eﬀects of the temperature on IC50 values. The IC50
values were obtained by adjusting the data to a dose-response
sigmoid equation for each glutamate analog at the three culture
temperatures.
Temperature MS MSE MSO
28◦C1 7 .0 ±0.35 8 .8 ±3.35 2 .6 ±4.3
33◦C2 0 .2 ±1.74 7 .1 ±7.93 2 .4 ±3.2
37◦C9 .4 ±1.53 7 .2 ±2.61 1 .1 ±0.7
be largely optimized by using the appropriate enantiomer.
Additionally, a quantitative determination of the glutamate
content would help to determine if the parasite is converting
the analogs in consumable substrates.
When T. cruzi invades the mammalian host cell, it is
exposed to diﬀerent environmental changes. Among these
changes are the acidic medium of the parasitophorous
vacuole, the reactive oxygen species (ROS) produced by the
host cells, changes in the nutrients availability, and high
temperature of mammalian host. All these factors acting
simultaneously with drugs could reduce parasite viability,
revealing the role of their targets on the resistance to these
stress conditions. We evaluated the viability of epimastigotes
under the interaction of analogs with thermal, nutritional
and oxidative stress. For thermal stress, we chose three
temperatures: 28◦C, the optimal temperature of growth
for the insect vector stages, 37◦C, the temperature of the
mammalian host, and 33◦C, the optimal temperature for
the progression of in vitro infection of mammalian cells
[13]. As previously reported [14], the maximum cell density
(between99±4×106 cellsmL−1 and141±4×106 cellsmL−1)
was reached when cultures were maintained at 33◦Ci n
spite of the fact that Asin and Catala observed an optimum
temperature of 28◦C[ 41], a discrepancy that can likely be
attributed to diﬀerences in the T. cruzi strain (Figure 2).
When the parasites were cultured at 37◦C( n e a r l yt h e
human temperature), the maximum cell density (28 ± 2 ×
106 cells×mL−1) diminished with respect to the standard
epimastigote temperature (91 ± 3 × 106 cells×mL−1)[ 14].
The IC50 was obtained for each analog and temperature.
Results indicated that the sensitivity of parasites to the
drugs was signiﬁcantly increased with temperature (Table 1)
being that the synergistic interaction between these factors
was signiﬁcant at 37◦C( P<. 01) (Figure 3). Interestingly,
the highest inhibitory interaction between a speciﬁc analog
and temperature was observed with MSO at 37◦C, which
produced an almost 5-fold reduction in the IC50 compared
to that obtained at 28◦C( Table 1).
To analyze the possible eﬀect of drugs on nutritionally
stressed parasites, three diﬀerent carbon sources were added
separately to each culture (glucose, glutamate, and proline).
The parasite can metabolize glutamate and proline to obtain
energy as well as glucose [6]. Then, the epimastigotes
were starved for 72h in PBS (PBS) or in 3mM glucose
(GLC),3mML-glutamate(GLU),or3mML-proline(PRO),
separately. The cultures were treated with the analogs at
concentrations near the IC50 obtained for parasite growth.Enzyme Research 5
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Figure 3: Dose-response curves of epimastigotes cultured at diﬀerent temperatures and concentrations of MS (a), MSE (b), and MSO (c)
treatment. The parasite growth inhibition was measured on the ﬁfth day of growth, submitted to thermal stress (• 33◦C, and
￿ 37◦C) or not
(
￿ 28◦C) and drug treatments. The curves correspond to the adjusting to sigmoidal dose-response equation at 28◦C( — ) ,3 3 ◦C( --- ) ,a n d
37◦C( ···). Insets: the maximum cell growth obtained in the control (no drug treatment) for each temperature is shown.
Untreated cells were used as controls. As expected, the pres-
ence of the three diﬀerent carbon sources contributed
to maintain parasite viability when compared with those
starved in just PBS (Figure 4). Each culture treated with
inhibitors showed signiﬁcant diﬀerences (P<. 01) when
compared to controls, except for those incubated with PBS
and MSE. Furthermore, MS and MSO produced greater
inhibition than MSE (Table 2). Again, these results indicate
thatMSEmaynotbeaneﬀectiveinhibitoragainst T. cruzi.As
evidenced in Figure 4 and Table 2,M Sr e v e r s e dt h ee ﬀect of
glutamate on viability, conﬁrming that this analog interferes
with glutamate metabolism.
To analyze the eﬀect of each drug on parasites subjected
to oxidative stress, the cultures were incubated for 90min
with PBS supplemented with or without 120μMH 2O2 and
1 0m MM S ,3 0m MM S E ,a n d2 5m MM S O .T h ec o m b i n e d
treatment withH2O2 andMSOorMSEshowed a statistically
Table 2: The eﬀect of the nutritional state of the parasites on
treatment with glutamate analogs. The inhibitory percentages (%)
were calculated from the viability of the epimastigotes obtained
in each starved condition with or without the addition of drug
(MS=20mM, MSE=60mM, and MSO=50mM).
Nutrients MS MSE MSO
PBS (no nutrients) 87 18 51
GLC 55 38 84
L-GLU 90 44 77
L-PRO 56 43 68
signiﬁcant synergistic eﬀect (P<. 01), whereas MS did not
show synergism (Figure 5). Following a previously presented
rationale[14],itcouldbeproposedthattheaugmentedeﬀect
oftheanalogsinthepresenceofH2O2 wasduetothefactthat
these reagents aﬀected glutamate- or glutamine-dependent6 Enzyme Research
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Figure 4: Response of epimastigotes to nutritional stress and MS (a), MSE (b), or MSO (c) treatment. Parasites were incubated for 72h in
PBS, 3mM glucose (GLC), 3mM glutamate (GLU), or 3mM proline (PRO), and treated with 20mM MS, 60mM MSE, or 50mM MSO.
The cell viability was evaluated using the MTT assay.
oxidativestress resistance mechanisms. Alternatively,itcould
be argued that the enhancement of the eﬀects of the analogs
seen under oxidative stress conditions was due to the fact
thatthesecompoundsmadethecellsmorefragilebypartially
arresting glutamate or glutamine metabolism.
To better understand both the involvement of gluta-
mate/glutamine metabolism in resistance to oxidative and
metabolic stresses as well as the interaction between these
factors and MSE, MSO, or MS treatments, a three-variable
experiment was performed: cell viability was evaluated as
a function of oxidative and metabolic stress challenges
and MSE, MSO, or MS treatment. The parasites were
maintained for 48h at the conditions previously described
for the nutritional stress experiment, then washed with
PBS and incubated for 3h with or without 80μMH 2O2.
After incubation, cell viability was evaluated. All three
drugs signiﬁcantly diminished (P<. 05) the epimastigote
viability after the 3-h incubation (with or without oxidative
stress) with respect to those not subjected to preincubation
(named To, see Figure 6). The absence of treatment with
analogs resulted in a diminished eﬀect of oxidative stress
(P<. 01).Theprotectionobservedinparasitesmaintainedin
3mM L-proline against oxidative stress had been previously
reported for several organisms [42, 43]a n df o rT. cruzi
[14]. In the same way, the glutamate analogs could act as
possible coadjuvants for therapeutic drugs by enhancing the
parasite sensitivity to ROS generated by the treatment with
nifurtimox or benznidazole [22]. The interaction between
the analogs and H2O2 was only synergistic (P<. 05) when
the parasites were previously incubated with glucose and
MS or MSE, glutamate and MSO, or proline and MSO
(Figure 6). As expected, these results conﬁrmed that the
nutritional state of the parasites is a main factor to be
takeninto account in the interpretation of these assays. Most
importantly, these data showed the existence of at least three
oxidative-stress resistance mechanisms involving glutamate-
related metabolic pathways: (1) MS and MSE interfere with
a glucose-dependant mechanism, (2) MSO, as expected,Enzyme Research 7
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Figure 5: Response of epimastigotes to oxidative stress and MS (a), MSE (b), or MSO (c) treatment. Exponential growth culture parasites
(control samples and samples treated with 10mMMS, 30mMMSE, or 25mMMSO) were resuspended in PBS and subjected either to
oxidative stress for 3h by addition of 120μMH 2O2 or to water as the control. After washings,cells were cultured in LIT and counted after 5
days to evaluate their recovery after treatments.
interferes with a glutamate-dependant mechanism, and (3)
MSO also interferes with a proline-dependant mechanism.
Other protection mechanisms that could be altered by the
tested analogs cannot be discarded. For example, it is known
that ROSs can oxidize the surface-exposed methionine
residues of proteins to methionine sulfoxides and this
damage could be repaired by two methionine sulfoxide
reductases [44, 45], a mechanism that occurs throughout
the aerobic world, from bacteria [35] to mammals [45, 46].
Theinterconversionofmethionineandmethioninesulfoxide
can function as a natural process to regulate the biological
activity of proteins [47]. Mechanisms that protect cells
against oxidative-stress are mainly important in the in vivo
infection establishment, or when parasites are exposed to
drugs used in the treatment of Chagas’ disease [22].
The eﬀect of these three glutamate analogs on the host-
cell viability (see Figure S1 in Supplementary Material avail-
able online at doi: 10.4061/2011/486928) and on the host
cell infection by trypomastigotes (Figure S2, Supplementary
Material) were also evaluated at three concentrations of each
drug (MS=10–20mM, MSO=30–50mM, and MSE=30–
50mM). No signiﬁcant inhibition on the trypomastigote
burst was observed (data not shown). This fact, together
with recent ﬁndings showing the inability of trypomastigotes
to recover the ATP levels after starvation on the basis of
glutamate as the sole carbon source [11], strongly supports
the idea that, for these forms, glutamate-based metabolism
is not relevant as glucose- or proline-based metabolism.
However, it should be taken into account that the mode of
action of nifurtimox and benznidazole includes free radicals
(nitroradicals) and the generation of electrophilic metabo-
lites, both of which are toxic for all forms of parasites. The
nitroradicals enter redox recycling with molecular oxygen,
producing partial oxygen reduction favoring the appearance
of ROSs. [22]. Due to the synergistic interaction between the
drugs utilized in this study and oxidative stress conditions, it
may be hypothesized that the use of these glutamate analogs
could help to decrease the clinical dose of currently used8 Enzyme Research
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Figure 6: The combined eﬀect of starvation, oxidative stress, and analogues treatments on epimastigotes. Parasites previously incubated in
PBS (PBS), 3mM L-proline in PBS (PRO), or 3mM glucose in PBS (GLC), and subjected either to oxidative stress for 3h by addition of
80μMH 2O2 or to water, were treated with or without (control) 20mM MS (a), 60mM MSE (b), or 50mM MSO (c). After washing, the
parasites were incubated for 3h in PBS and stressed by the addition of 80μMH 2O2. The cell viability was evaluated by MTT assay.
drugs, thereby diminishing the side eﬀects or the length
of therapy. Our enzymatic data for the reaction catalyzed
by the NADP+-linked glutamate dehydrogenase revealed a
higher rate in the direction of the reductive amination
of α-ketoglutaric acid producing L-glutamate (NADPH+-
glutamate dehydrogenase) than the oxidative deamination
of L-glutamate (NADP+-glutamate dehydrogenase) (Figures
7(a) and 7(b)). For this later reaction, no signiﬁcant diﬀer-
ences were observed in the presence of L-glutamate and the
analogs tested (Figure 7(a)). The data obtained for the gluta-
mate dehydrogenase activities (1.56±0.23U/mg for NADP+
GDH and 42.22 ± 3.52U/mg for NADPH+ GDH) suggest
a preference for the glutamate synthesis in the epimastigote
stage of T. cruzi (Figures 7(a)-7(b))[ 18–20]. Indeed, we also
have showed the enzymatic activity levels increased when
the glutamate analogs are added (Figure 7(b)). This result
shows that T. cruzi, in the conditions above described, would
convert these compounds producing oxidized equivalents
which are detected by the method herein used. However,
further analytical methods are necessary to elucidate the
intermediates produced under these conditions. The pres-
ence and enzymatic activity for GS was conﬁrmed in T.
cruzi epimastigotes, suggesting a nutritional requirement for
glutamine.This process isATP-dependent and theglutamine
produced would be transaminated (EC: 2.6.1.16) releasing
D-glucosamine-6-phosphate. This product is an interme-
diate of the amino sugars metabolism necessary for the
glycoproteins surface synthesis [48]. The speciﬁc activities
for GS did not show diﬀerences in the presence of any of
the glutamate analogs tested (Figure 7(c)). All these dataEnzyme Research 9
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Figure 7: Speciﬁc activities for three enzymatic reactions of the glutamate metabolism. Epimastigotes cells (5.0 × 10
8 cells) were used to
prepare the crude extracts as enzyme source. The proteins were quantiﬁed by the Bradford’s method andthe activities forNADP+-glutamate
dehydrogenase and glutamine synthetase (GS) were measured. Due to reversibility of the glutamate dehydrogenase reaction, the enzymatic
activity was measured in both ways, the reductive amination of α-ketoglutaric acid (NADPH+-GDH) and the oxidative deamination of L-
glutamate (NADP+-GDH). The bars represent the speciﬁc activities in the presence of the natural substrate, as control, and 15mM of each
glutamate analog tested. The graphic was the resultant of three replicates done separately.
support the hypothesis that T. cruzi capability to metabolize
thesecompoundsinterferes inthetrypanocidal eﬀectsherein
evaluated.The highervaluesofIC50 f orth es ec om poun dsa r e
in accordance with the enzymatic proﬁles exhibited, even in
concentrations of 15mM. for MS, MSE, and MSO.
3.Materialsand Methods
3.1. Reagents. L-glutamate, L-proline, L-methionine sulfox-
imine, DL-methionine sulfoxide, DL-methionine sulfone,
rotenone, antimycin, and 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) were purchased from
Sigma Aldrich (Saint Louis, MO, USA). RPMI culture
medium and fetal calf serum were purchased from Cultilab
(Campinas, SP, Brazil). All other reagents were purchased
from Amresco.
3.2. Cells and Parasites. The Chinese hamster ovary cell
line, CHO-K1, was routinely cultivated in RPMI medium
(Gibco BRL) supplemented with 10% heat-inactivated fetal
calf serum (FCS), 0.15% (w/v) NaHCO3 at 37◦Ci nah u m i d
atmosphere containing5%CO2 aspreviouslydescribed[14].
Epimastigotes of T. cruzi, CL strain, clone 14 [49]w e r e
maintained at the exponential growth phase by subculturing
every 48h in liver infusion-tryptose (LIT) medium supple-
mented with 10% FCS at 28◦C[ 50]. Trypomastigotes were10 Enzyme Research
obtained by infecting CHO-K1 cells with trypomastigotes,
as previously described [13, 51]. Trypomastigotes were
collected in the extracellular medium from the sixth day on.
3.3. Inhibition Growth Assays. Epimastigotes in the expo-
nential growth phase (approximately 5.0 × 107 cellsmL−1)
were centrifuged and resuspended in fresh LIT medium.
Then,aninoculumof2.5×106 epimastigotesmL−1 wasused.
The assays were carried out using 200μL of LIT medium,
supplemented with diﬀerent drug concentrations or without
drug treatment (control), on 96 well plates, and maintained
at28◦C.Cellgrowthwas estimatedbyabsorbance readings at
620nm every day for a total of 10 days. The optical densities
(absorbance) were transformed into cell density values
(cellsmL−1) using a calibration linear equation previously
obtained from the same conditions (R2 = 0.9981). The con-
centration of analogs that inhibited 50% of parasite growth
(IC50) was determined at the exponential-phase of growth
(ﬁfth day) by adjusting the eﬀect (growth inhibition values)
as a function of drug concentration to a classical sigmoidal
equation. As a control for cell growth inhibition, growth
curveswere runin parallel forall theexperiments inmedium
containing 200μM rotenone and 0.5μM antimycin [52].
3.4. The Eﬀect of Glutamate Analogs on Growth Inhibition in
Stress Conditions. To analyze the combined eﬀect of gluta-
mate analogs at diﬀerent temperatures, the growth curves
were performed as described above and by incubating the
cultures at 33◦Ca n d3 7 ◦C. To evaluate the combined eﬀect
of drugs and nutritional stress, 2.0 ×107 epimastigotesmL−1
were washed twice and resuspended in PBS or in PBS
supplemented with 3mM L-glutamate, 3mM L-proline, or
3mM glucose. Additional cultures were used in the same
conditionsbutwith theaddition of20mMMS,60mM MSE,
or 50mM MSO. The parasites were maintained at 28◦Cf o r
72h. Then, cell viability was measured by adding 20μLo f
MTT (5mgmL−1) at 100μL of cultures in PBS. The cells
were maintained at 28◦C, and after three hours the reaction
was stopped by adding 20μL of 10% SDS. The viability
was estimated by reading the optical density at 595nm
and subtracting background values read at 690nm [14].
To evaluate the inhibition of epimastigote growth induced
by the three analogs under oxidative stress conditions,
5 × 106 parasitesmL−1 from stationary phase cultures were
washedtwicewithPBS,andincubatedfor90mininPBSwith
or without (control) 120μMH 2O2, and in the presence or
not of analogs at 10mMMS, 30mMMSE, or 25mMMSO
(half IC50 concentrations). Then, the cells were collected by
centrifugation and resuspended in LIT medium, and after a
5-day incubation, the number of cellsmL−1 was determined
as previously described [53]. To evaluate the combined
eﬀect of starvation and oxidative stress with drugs, 2.0 ×
107 epimastigotesmL−1 were washed twice and preincubated
for 48h at 28◦C in PBS supplemented with or without 3mM
L-glutamate, 3mM L-proline, or 3mM glucose. Additional
cultures were run in the same conditions but with the addi-
tionof20mMMS,60mMMSE,or50mMMSO(concentra-
tions close to the obtained IC50). The cells were then washed
twice and resuspended in PBS with or without the addition
of 80μMH 2O2, and maintained in those conditions at 28◦C
for3h. Then, cell viability wasestimated by MTT assay [14].
3.5. Eﬀect of Glutamate Analogs on Mammalian Cell Viability.
CHO-K1 cells (5.0 × 105 cellsmL−1)w e r ei n o c u l a t e di n2 4
well plates in FCS-supplemented RPMI medium as previ-
ously described, in the presence of increasing concentrations
of analogs or not (controls). The viability of cells was
determined by MTT assay and the IC50 was obtained from
theadjustmentofthedatatoatypicaldose-response sigmoid
equation.
3.6. Eﬀect of Glutamate Analogs on the Trypomastigote
Bursting from Infected Cells. CHO-K1 cells were infected
with trypomastigotes in RPMI medium supplemented with
10% FCS. After 3h at 37◦C, free trypomastigotes in the
medium were removed by washing with PBS and the
infected cells were maintained at 33◦Ci nR P M Im e d i u m
supplemented with 2% FCS in the presence of diﬀerent
concentrations of glutamate analogs, or without analogs
in the case of the control. Fresh medium containing the
respective drug was added every day during the intracellular
cycle of the parasite. The trypomastigotes were collected in
the extracellular medium on the seventh day, and counted in
a hemocytometer as previously described [13, 14].
3.7. Eﬀect of Glutamate Analogs on Enzymatic Activities.
In order to determine if the glutamate analogs used in
this study would impair the speciﬁc activities involved
in the glutamate-metabolism enzymes, we have measured,
separately, the enzymatic activity for three reactions. The
measurements for the NADP+-linked glutamate dehydroge-
nase (GDH) [EC 1.4.1.4] were done in both senses [18, 20].
The activities for the reductive amination of α-ketoglutaric
acid with NADPH dependence (NADPH+-GDH) and the
oxidative deamination of L-glutamate with NADP+ depen-
dence (NADP+-GDH) were determined. Additionally, the
glutamine synthetase activity (GS) [EC 6.3.1.2] was also cal-
culated [21]. In the three cases, the measurements were done
in the presence or not of the glutamate analogs MS, MSO,
and MSE(sigma). Total cell-free extracts were prepared from
epimastigotes forms (5.0 × 108 cells) at mid-log phase (3rd
day). The cells were harvested by centrifugation at 2000 × g
and washed three times with saline phosphate buﬀer1X pH:
7,4. The resultant pellet was resuspended in lysis buﬀer con-
taining Tris-HCl 20mM pH: 7.9, Triton X-100 0.1%, sucrose
0.25M, phenylmethanesulfonylﬂuoride (PMSF) 1mM, and
30μL of protease inhibitor cocktail (sigma). The cells were
broken by three cycles of sonication/ice during 20s at 40%
of potency. Soluble material was separated by centrifugation
at 12,000 × g( 4 ◦C—15min) and the supernatant collected.
This fraction was passed through a desalting column (PD-
10) and eluted with KH2PO4 50mM pH: 7.4 for enzymatic
activity assays. Total proteins concentration was determined
by the Bradford’s method [54] using bovine serum albumin
as standard.Enzyme Research 11
3.7.1. Glutamate Dehydrogenase (NADP+-GDH ). The assay
reaction mixture (1.5mL) for determination of NADP+-
GDH activity contained Tris-HCl 50mM pH: 8.6, β-nic-
otinamide adenine dinucleotide phosphate sodium salt tri-
hydrate (β-NADP) 25mM, sodium glutamate 20mM. The
reactionwas started by the additionof crudeextract (100μg)
and incubated at 30◦C for 5min. The increasing of the ab-
sorbance at 340nm was monitored and a blank without the
enzyme addition was used. When necessary, 15mM of each
analog was added to the reaction mix and the corresponding
activity was recorded. One activity unit (U) is deﬁned as
the amount of enzyme in the crude extract required to
catalyze the formation of 1μmol of α-ketoglutaric acid from
L-glutamate per minute at 30◦C.
3.7.2. Glutamate Dehydrogenase (NADPH+-GDH). The
assay reaction mixture (1.5mL) for determination of
NADPH+-GDH activity contained Tris-HCl 83mM pH: 8.3,
α-ketoglutaric acid (α-KG) 7.5mM, NH4Cl 225mM, and
β-nicotinamide adenine dinucleotide phosphate, reduced
form, (β-NADPH)0.25mM (sigma). The reaction was start-
ed by the addition of crude extract (100μg) and incubated at
30◦C for 5min. The increasing of the absorbance at 340nm
was monitored and a blank without the enzyme addition
was used. When necessary, 15mM of each analogue was
added to the reaction mix and the corresponding activity
was recorded. One activity unit (U) is deﬁned as the amount
of enzyme in the crude extract required to catalyze the
formation of 1μmol of L-glutamic acid from α-ketoglutaric
acid per minute at 30◦C.
3.7.3. Glutamine Synthetase (GS). A coupled method using
the pyruvate kinase/L-lactic dehydrogenase enzymes was
necessary for the GS activity determination. The assay
reaction mixture (1.5mL) contained imidazole-HCl buﬀer
34.1mM pH: 7.4, sodium glutamate 12mM, adenos-
in 5 -triphosphate 8.5mM, phosphoenolpyruvate (PEP)
1.5mM, MgCl2 60mM, KCl 18.9mM, NH4Cl 45mM, β-
nicotinamide adenine dinucleotide 0.25mM, 28 units of
pyruvate kinase and 40 units of L-lactic dehydrogenase
(sigma). The reaction was started by the addition of crude
extract (100μg) and incubated at 30◦Cf o r1 0 m i n .T h e
increasing of the absorbance at 340nm was monitored and
a blank without the enzyme addition was used. When
necessary, 15mM ofeach analogue was added tothe reaction
mix and the corresponding activity was recorded. One
activity unit (U) is deﬁned as the amount of enzyme in the
crude extract required to catalyze the formation of 1μmol of
L-glutamine from L-glutamic acid per minute at 30◦C.
3.8. Statistical Analysis. A one-way analysis of variance
(ANOVA) followed by a Dunnet’s test was used for statistical
analysis. A P value less than.05 was considered statistically
signiﬁcant. To analyze synergism in the interaction between
the two independent treatments, a two-way ANOVA was
performed as described [55].
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